Randomized, Double-Blind, Phase II Trial Comparing Gemcitabine-Cisplatin plus the LTB4 Antagonist LY293111 versus Gemcitabine-Cisplatin plus Placebo in First-Line Non–Small-Cell Lung Cancer
Keywords: Cisplatin; Gemcitabine; hemotherapy; Leukotriene receptor agonist; Lung cancer; LY293111; Peroxisome proliferators; Activated receptor γ agonist